Quince Therapeutics, Inc. 8-K

What Happened
Quince Therapeutics, Inc. (QNCX) filed an 8-K on May 18, 2026 to report it completed the acquisition of Orphai Therapeutics (via a Merger Agreement dated May 17, 2026). The deal was structured as a two-step merger intended to qualify as a tax‑free reorganization. At closing, Quince issued 3,258,517 shares of common stock and 67,101.235 shares of Series C Non‑Voting Convertible Preferred Stock (each Series C share convertible into 1,000 common shares, subject to conditions). The company also filed a Certificate of Designation for the Series C Preferred and issued related press releases and an investor presentation, including a Phase 2a LAM‑001 update presented at the American Thoracic Society conference.

Key Details

• Closing date: May 18, 2026; Merger Agreement dated May 17, 2026; transaction intended to be U.S. federal income tax‑free.
• Securities issued: 3,258,517 common shares and 67,101.235 shares of Series C Preferred (each convertible into 1,000 common shares — ~67.1 million possible common shares upon conversion, subject to conditions).
• Board & executive changes: Dr. Brigette Roberts appointed as Class III director and Chief of Corporate Affairs (effective at closing); her annual base salary is $600,000 with a 50% target bonus under the employment letter.
• Retention payments: Board approved retention bonuses of $700,000 for Dirk Thye (CEO & CMO) and $500,000 for Brendan Hannah (COO/CBO/CCO), payable if each remains employed through the approval of the Company Stockholder Matters.

Why It Matters
This acquisition brings Orphai’s pulmonary franchise (including inhaled rapamycin program LAM‑001) into Quince’s pipeline and installs Orphai leadership into Quince management, which could accelerate clinical development in pulmonary indications. The issuance of common stock and a large block of convertible preferred stock is material for investors because, if conversion conditions are met, it could substantially increase Quince’s outstanding share count and dilute existing shareholders. Investors should watch for further detail on conversion terms, any shareholder votes referenced by the filing, integration plans for Orphai’s assets, and upcoming clinical or financing updates referenced in the company’s press materials.